Major Finding: Abrupt discontinuation of natalizumab coincided with a surge in gadolinium-enhancing lesions on MRI that mostly resolved by 9 months without any clinical deterioration.
Data Source: Case series of 11 patients who had received natalizumab infusions before abruptly discontinuing the therapy
Disclosures: Dr. Khan said the study was independently funded and he did not have any financial declarations to make.
PREVIEW